HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Deficiency of the two-pore-domain potassium channel TREK-1 promotes hyperoxia-induced lung injury.

AbstractOBJECTIVES:
We previously reported the expression of the two-pore-domain K channel TREK-1 in lung epithelial cells and proposed a role for this channel in the regulation of alveolar epithelial cytokine secretion. In this study, we focused on investigating the role of TREK-1 in vivo in the development of hyperoxia-induced lung injury.
DESIGN:
Laboratory animal experiments.
SETTING:
University research laboratory.
SUBJECTS:
Wild-type and TREK-1-deficient mice.
INTERVENTIONS:
Mice were anesthetized and exposed to 1) room air, no mechanical ventilation, 2) 95% hyperoxia for 24 hours, and 3) 95% hyperoxia for 24 hours followed by mechanical ventilation for 4 hours.
MEASUREMENTS AND MAIN RESULTS:
Hyperoxia exposure accentuated lung injury in TREK-1-deficient mice but not controls, resulting in increase in lung injury scores, bronchoalveolar lavage fluid cell numbers, and cellular apoptosis and a decrease in quasi-static lung compliance. Exposure to a combination of hyperoxia and injurious mechanical ventilation resulted in further morphological lung damage and increased lung injury scores and bronchoalveolar lavage fluid cell numbers in control but not TREK-1-deficient mice. At baseline and after hyperoxia exposure, bronchoalveolar lavage cytokine levels were unchanged in TREK-1-deficient mice compared with controls. Exposure to hyperoxia and mechanical ventilation resulted in an increase in bronchoalveolar lavage interleukin-6, monocyte chemotactic protein-1, and tumor necrosis factor-α levels in both mouse types, but the increase in interleukin-6 and monocyte chemotactic protein-1 levels was less prominent in TREK-1-deficient mice than in controls. Lung tissue macrophage inflammatory protein-2, keratinocyte-derived cytokine, and interleukin-1β gene expression was not altered by hyperoxia in TREK-1-deficient mice compared with controls. Furthermore, we show for the first time TREK-1 expression on alveolar macrophages and unimpaired tumor necrosis factor-α secretion from TREK-1-deficient macrophages.
CONCLUSIONS:
TREK-1 deficiency resulted in increased sensitivity of lungs to hyperoxia, but this effect is less prominent if overwhelming injury is induced by the combination of hyperoxia and injurious mechanical ventilation. TREK-1 may constitute a new potential target for the development of novel treatment strategies against hyperoxia-induced lung injury.
AuthorsAndreas Schwingshackl, Bin Teng, Patrudu Makena, Manik Ghosh, Scott E Sinclair, Charlean Luellen, Louisa Balasz, Cynthia Rovnaghi, Robert M Bryan, Eric E Lloyd, Elizabeth Fitzpatrick, Jordy S Saravia, Stephania A Cormier, Christopher M Waters
JournalCritical care medicine (Crit Care Med) Vol. 42 Issue 11 Pg. e692-701 (Nov 2014) ISSN: 1530-0293 [Electronic] United States
PMID25126877 (Publication Type: Comparative Study, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Cytokines
  • Potassium Channels, Tandem Pore Domain
  • potassium channel protein TREK-1
Topics
  • Acute Lung Injury (etiology, pathology, therapy)
  • Animals
  • Blotting, Western
  • Bronchoalveolar Lavage Fluid (chemistry)
  • Cytokines (genetics, metabolism)
  • Disease Models, Animal
  • Enzyme-Linked Immunosorbent Assay
  • Hyperoxia (complications)
  • Macrophages, Alveolar (metabolism)
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Microscopy, Confocal (methods)
  • Potassium Channels, Tandem Pore Domain (deficiency, metabolism)
  • Random Allocation
  • Real-Time Polymerase Chain Reaction
  • Reference Values
  • Respiration, Artificial
  • Risk Assessment
  • Severity of Illness Index

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: